Eating Disorders & GLP-1 RAs

About this resource

Glucagon-like peptide-1receptor agonists (GLP-1 RAs), such as semaglutide (Ozempic), are medications originally developed to treat type 2 diabetes. LP-1 RAs are now being used as an approved or off-label treatment for weight loss.

here is limited research available to help researchers, clinicians, and patients/consumers to understand the relationships between GLP-1 RAs and eating disorders (9). However, it is thought that GLP-1 RAs may negatively impact eating disorder symptomology and treatment in a number of ways.

This factsheet provides information for clinicians, researchers, and patients/consumers to understand more about the link between GLP-1 RAs and eating disorders, including risks, physical impacts, psychological impacts, and practice recommendations.

PDF Available ?Yes
Year2025

See also

Issue 72: Body Image, Social Media and Eating Disorders - Part 1

Editor’s Note Introduction of new NEDC body image fact sheet Associate Professor Rachel F.

Read more

EDNA Information Sheet - Neurodivergent People

This information sheet has been developed by Eating Disorders Neurodiversity Australia.

Read more

Stepped System of Care - Spanish

La National Eating Disorders Collaboration (NEDC) ha integrado dos décadas de consenso del sector y experiencia vivida y desarrollo de servicios en un modelo del sistema escalonado de atención para los trastornos alimentarios (Figura 1).

Read more